Experimental Lilly combination drug tops Zepbound in weight-loss trial

Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its ​blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk fo...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。